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Background: L(-)-carnitine production has been widely studied because of its beneficial properties on various
diseases and dysfunctions. Enterobacteria possess a specific biotransformation pathway which can be used for the
enantioselective production of L(-)-carnitine. Although bioprocesses catalyzed by enzymes or whole cells can
overcome the lack of enantioselectivity of chemical methods, current processes for L(−)-carnitine production still
have severe disadvantages, such as the low yields, side reactions and the need of high catalyst concentrations and
anaerobic conditions for proper expression of the biotransformation pathway. Additionally, genetically engineered
strains so far constructed for L(-)-carnitine production are based on plasmids and, therefore, suffer from
segregational unstability.
Results: In this work, a stable, high yielding strain for L(-)-carnitine production from low cost substrates was
constructed. A metabolic engineering strategy was implemented in a multiple mutant for use in both growing and
resting cells systems. The effect of mutations on gene expression and metabolism was analyzed to characterize the
productivity constraints of the wild type and the overproducer strains. Precise deletion of genes which encode
proteins of central and carnitine metabolisms were performed. Specifically, flux through the TCA cycle was
increased by deletion of aceK (which encodes a bifunctional kinase/phosphatase which inhibits isocitrate
dehydrogenase activity) and the synthesis of the by-product γ-butyrobetaine was prevented by deletion of caiA
(which encodes a crotonobetainyl-CoA reductase). Both mutations led to improve the L(-)-carnitine production by
20 and 42%, respectively. Moreover, the highly regulated promoter of the cai operon was substituted by a
constitutive artificial promoter increasing the biotransformation rate, even under aerobic conditions. Resting cells of
the BW ΔaceK ΔcaiA p37cai strain produced 59.6 mmol l-1 · h-1 of L(−)-carnitine, doubling the productivity of the
wild type strain. In addition, almost total conversion was attained in less than two hours without concomitant
production of the side product γ–butyrobetaine.
Conclusions: L(-)-carnitine production has been enhanced by strain engineering. Metabolic engineering strategies
herein implemented allowed obtaining a robust and high yielding E. coli strain. The new overproducer strain
attained almost complete conversion of crotonobetaine into L(-)-carnitine with growing and resting cells, and even
under aerobic conditions, overcoming the main environmental restriction to carnitine metabolism expression. So
far, this is the best performing L(-)-carnitine production E. coli strain described.
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Worldwide, the demand of L(-)-carnitine [R(−)-3-hy-
droxy-4-trimethylaminobutyrate] is increasing due to its
multiple applications as pharmaceutical and nutraceut-
ical product, hence the need of developing more efficient
production methods. Chemical synthesis yields a ra-
cemic mixture of D,L-carnitine, which cannot be admin-
istered to patients [1-4]. The natural enantioselectivity of
microbial and enzymatic biotransformations offers an
advantage over classical chemical synthesis. Several bio-
logical processes have been developed for the production
of L(-)-carnitine from non-chiral precursors [5-12] espe-
cially using strains belonging to the genera Escherichia
and Proteus. At the industrial level, Lonza belongs a
proprietary strain of a non-disclosed genus branching
between Agrobacterium and Rhizobium and close to Rhi-
zobium meliloti [13].
Crotonobetaine (dehydrated D,L-carnitine) and D(+)-car-
nitine are by-products from the chemical L(-)-carnitine
production process (Figure 1A), which can be transformed
into L(-)-carnitine. This enantioselective biotransformation
has the potential to enhance the overall economic and
environmental viability of the chemical synthesis process.
In this respect, the L(-)-carnitine metabolism in E. coli has
been widely studied and characterized [5,6,14-16] because
of its role in anaerobic respiration, and stress survival,
especially in osmoprotection [17-19]. E. coli is able to trans-
form crotonobetaine into L(-)-carnitine through a series of
sequential steps. Substrates and products are transported
by a specific membrane antiporter (CaiT) [20]. All bio-
chemical steps occur at the level of coenzyme A thioesters:
activation of betaines involves an ATP-dependent CoA-
ligase (CaiC), and a crotonobetainyl-CoA:carnitine CoA-
transferase (CaiB) which inexpensively exchanges the CoA
moiety between betaines [16,21-23]. The enantioselective
hydration is catalyzed by a crotonobetainyl-CoA hydratase
(CaiD) [16,22]. As a side reaction, crotonobetaine can be
reduced to γ-butyrobetaine by means of a crotonobetainyl-
CoA reductase (CaiA) [16,24], a respiration process whichFigure 1 Synthesis of L(-)-carnitine. (A) Chemical synthesis of L(-)-carnitin
compounds in E. coli. Biotransformation of crotonobetaine into L(-)-carnitin
γ-butyrobetaine; CaiT: L(-)-carnitine/crotonobetaine/γ-butyrobetaine protein
CaiC: L(-)-carnitine, crotonobetaine or γ-butyrobetaine CoA-ligase; CaiD: crois inhibited by electron acceptors such as oxygen or fumar-
ate (Figure 1B). All these activities are encoded by two di-
vergent operons: caiTABCDE, which encodes the carnitine
biotransformation enzymes [25], and fixABCX, which en-
codes putative flavoproteins involved in anaerobic carnitine
respiration [26,27]. Both are expressed from a common
intergenic promoter-operator region, which is tightly regu-
lated by cAMP-CRP, FNR, and the specific transcriptional
activator CaiF [28]. Expression of caiF is activated by
cAMP-CRP and FNR, which regulates the expression of
hundreds of genes under anaerobic conditions [29-31]. So
far, carnitine production by E. coli is carried out in anaer-
obic conditions to induce the expression of the cai operon,
as described in the current model of regulation [5,6,15].
With the aim of developing a combined and sustain-
able chemical-biotechnological process for industrial
production of L(-)-carnitine, we have previously reported
several strategies to enhance the biotransformation of
inexpensive substrates such as crotonobetaine or D
(+)-carnitine. Previous approaches focused on the use of
high cell density cultures, immobilized or resting cells
[11,14,32]. Up to 40-60% crotonobetaine conversion was
obtained with the wild type, non pathogenic, E. coli
O44K74 strain [32,33], and 60-70% using recombinant E.
coli strains overexpressing either the carnitine-CoA ligase
or the crotonobetainyl-CoA hydratase genes (encoded by
caiC and caiD, respectively) [34,35].
The major drawbacks of previous processes are the
low conversion yields and the production of the side-
product γ-butyrobetaine. Despite high volumetric produc-
tivities, the conversion yield could be improved, since the
presence of excess (non-transformed) substrates and by-
products in the biotransformation medium seriously
hinders downstream processing. Moreover, the cai/fix op-
erons are only expressed under anaerobic conditions, with
a concomitantly decreased energetic efficiency, and the
need to supplement the medium with fumarate to inhibit
the carnitine respiration pathway. In addition, using
plasmid-transformed strains in large scale cultivatione and crotonobetaine. (B) Metabolism of trimethylammonium
e. Abbreviations: L(-)-Car: L(-)-carnitine; Crot: crotonobetaine; γ-BB:
transporter; CaiB: crotonobetainyl-CoA:L(−)-carnitine CoA-tranferase;
tonobetainyl-CoA hydratase. Adapted from [6].
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pensive inducers and antibiotics. Moreover, plasmids can
be lost as a result of inefficient segregation between
daughter cells and the high metabolic burden imposed by
the maintenance of this extra genetic material [14,36].
Overall, all these constraints further restrict the econom-
ics of the bioprocess, preventing its implementation in an
industrial scale.
This work aims at improving L(-)-carnitine production
in E. coli by strain engineering techniques, overcoming
the major drawbacks previously exposed. All modifica-
tions were performed at the chromosomal level in order
to obtain genetically stable, marker-free, high-yielding
strains.
Results
Strain engineering for L(-)-carnitine production
On the basis of previous knowledge, three strategies
were designed to enhance carnitine production, dealing
with either central or secondary metabolism: (i) altering
the glyoxylate shunt/TCA cycle flux ratio at the isocitrate
node, (ii) avoiding the reduction of crotonobetaine to γ-
butyrobetaine (carnitine respiration pathway), and (iii)
enhancing the expression of the L(-)-carnitine operon
structural (caiTABCDE) or regulatory genes (caiF) to re-
lieve repression by aerobic conditions (Figure 2). All mod-
ifications were performed in E. coli BW25113, in which L
(-)-carnitine productivity is in the same order of magni-
tude as in the well characterized E. coli O44K74 strain. ToFigure 2 Strain engineering strategy followed to improve L(−)-carniti
replacement of the endogenous cai operon promoter and regulatory sequ
Replacement of the endogenous caiF promoter and a close regulatory regdetermine the effect on L(-)-carnitine production, the
strains were cultured anaerobically in LB-CB medium.
First, as regards the modification of central metabolism,
the genes encoding isocitrate lyase (aceA) and isocitrate
dehydrogenase phosphatase/kinase (aceK) were deleted.
The aceK knockout strain (devoid of post-translational
control of isocitrate dehydrogenase) showed a modest im-
provement in the production of L(-)-carnitine (20%), while
deletion of aceA (encoding the first enzyme of the
glyoxylate shunt) only had a slight effect (6%) (Figure 3).
No further improvement was observed in the aceAK
double mutant.
Second, to avoid the reduction of crotonobetainyl-CoA
into γ-butyrobetainyl-CoA, the caiA gene (encoding the
crotonobetainyl-CoA reductase) was deleted (Figure 1),
leading to an improvement in L(-)-carnitine production of
42% (Figure 3). The side-reaction was effectively suppressed
since no γ-butyrobetaine was detected in the supernatant
of any of the ΔcaiA strains assayed (results not shown).
Furthemore, the expression of the carnitine metabol-
ism structural (cai operon) and regulatory (caiF) genes
was tuned using artificial promoters (Figure 2), eliminat-
ing the repression by aerobic conditions. When the
endogenous promoters were replaced by constitutive
artificial promoters, L(-)-carnitine production increased
51% and 20% in the BW p37cai and BW p8caiF strains,
respectively (Figure 3).
Altogether, statistically significant differences in the
specific L(-)-carnitine production rates were observedne production in E. coli BW25113. (A) Deletion of the caiA gene and
ences (FNR and CRP binding sites) by the p37 artificial promoter. (B)
ion (FNR and CRP binding sites) by the p8 artificial promoter.
Figure 3 Effect of the mutations of central and secondary metabolism on L(-)-carnitine production. Experiments were performed in LB
medium supplemented with 50 mM crotonobetaine (LB-CB) in the absence and presence of fumarate and under aerobic and anaerobic
conditions. Anaerobic cultures: (A) LB-CB medium and (B) LB-CB medium supplemented with 12.5 mM fumarate. Aerobic cultures: (C) LB-CB
medium and (D) LB-CB medium supplemented with 12.5 mM fumarate. Bars represent the L(-)-carnitine yield after 24 h and dots represent the
specific growth rate. Discontinuous line indicates the maximum production (corresponding to 50 mM L(−)-carnitine). Adjusted p-values for
ANOVA (p < 0.001) and Tukey test of L(-)-carnitine production, *p < 0.05, **p < 0.01, ***p < 0.001.
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titers were achieved by the BW p37cai and BW ΔcaiA
strains (21.7 and 20.7 mM respectively) (Figure 3A).
To further study these strains with single modifica-
tions, growth and carnitine production rates were also
determined in anaerobic cultures in the presence of
fumarate (Figure 3B) (used as an alternative electron
acceptor [24,33]). The BW ΔcaiA strain reached the
highest production, 28.7 mM (p < 0.001) (Figure 3B) and
a similar 20-30% increase in the specific growth rate was
observed for all the strains with single modifications.
To further enhance productivity, all modifications that
positively affected L(−)-carnitine production, namely,
deletion of aceK and caiA and replacement of the cai
promoter, were implemented in the same strain. Given
its close proximity to the cai operon promoter, the caiAgene was deleted combining FRT and loxP sites in order
to avoid the deletion of the contiguous caiT gene
(Figure 2). As expected, the mutations did not affect
growth significantly. Nevertheless, the specific L(-)-car-
nitine production rate was higher than in the single mu-
tants. In order to check the effect of the mutations in
the BW ΔaceK ΔcaiA p37cai strain compared to the
wild type, expression of genes belonging to the cai/fix
operons was analyzed by qRT-PCR. Upstream (caiT) and
downstream (caiB and caiC) genes of the deleted caiA
were analyzed in order to assess whether a polar effect
appeared due to this deletion. As expected, the constitu-
tive promoter increased the expression of the carnitine
metabolism genes. However, caiB and caiC exhibited a
lower level of expression in the ΔcaiA strains (Table 1),
indicating that caiA deletion exerts a polar effect. In
Table 1 Relative gene expression in the engineered
strains growing anaerobically on LB-CB medium
supplemented with 12.5 mM fumarate
Strains caiT caiB caiC fixA
BW ΔcaiA 1.443 ± 0.20 0.86 ± 0.21 0.81 ± 0.06 1.32 ± 0.19
BW ΔaceK p37cai 3.00 ± 0.16 3.08 ± 0.24 2.18 ± 0.20- 1.95 ± 0.17
BW ΔaceK ΔcaiA
p37cai
3.23 ± 0.17 1.76 ± 0.10 1.47 ± 0.12 1.84 ± 0.10
For each gene, the transcription level of that gene in the wild type strain was
used as reference to normalize the data. Relative gene expression in the wild
type strain is, therefore, taken as 1. The results are the averages of three
independent measurements of each gene/condition in three
independent experiments.
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the fix operon (Table 1). This finding is not surprising,
since the cai and fix operons are expressed from a com-
mon intergenic control region [29].
Furthermore, the single (BW ΔaceK and BW ΔcaiA),
double (BW ΔaceK p37cai), and triple (BW ΔaceK
ΔcaiA p37cai) mutants and the wild type strain were
grown in the absence (Figure 3A) and presence of fu-
marate (Figure 3B) under anaerobic conditions in LB-CB
medium (Figure 3A, B). The combination of all three
mutations contributed to the highest increase of specific
L(-)-carnitine production rate (which doubled both in
absence and presence of fumarate) and yield (reaching
70% and 92% of conversion, respectively). The highest
titer obtained was 46 mM L(-)-carnitine with the BW
ΔaceK ΔcaiA p37cai strain (Table 2, Figure 3B).
Biotransformation under aerobic conditions
As described before, it might be desirable to produce L
(-)-carnitine under aerobic conditions with engineered
strains that constitutively overexpressed the caiF gene
and the cai operon. Tuning gene expression with artificial
oxygen-independent promoters should allow reaching this
goal and overcoming the limitations exhibited by the wild
type strain [37,38].
Indeed, the engineered strains produced L(-)-carnitine
under aerobic conditions when either the endogenous
promoters pcaiF or pcai were replaced by the constitu-
tive promoters p8 or p37, respectively. As expected, the
wild type, BW ΔaceK, and BW ΔcaiA strains were not
able to produce L(-)-carnitine (Figure 3C, D). The pres-
ence of fumarate did not affect the maximum specific
growth rate, being 0.84 h-1 for cultures without fumarate
and 0.86 h-1 for cultures supplemented with fumarate,
although enhanced L(−)-carnitine production as in an-
aerobic cultures (Figure 3C and D). The L(−)-carnitine
yield was higher in the strains that harbored the p37-
promoter upstream the cai operon. Nevertheless, the ac-
tivity of the promoter p8 was sufficient to activate the
expression of carnitine metabolism and to produce L
(-)-carnitine aerobically in the BW p8caiF strain. Forp37-mutants, the biotransformation yield ranged be-
tween 40-60%. In spite of the fact that the strain with
the highest specific carnitine production rate was BW
ΔaceK p37cai, the strain BW ΔaceK ΔcaiA p37cai
showed the highest L(-)-carnitine yield when reached
the stationary phase in the presence of fumarate (p <
0.001), obtaining 31.2 mM L(-)-carnitine. Altogether, the
modifications performed allowed aerobic L(-)-carnitine
production, although titers obtained were lower than
under anaerobic conditions (Figure 3).Biotransformation with resting cells
Biotransformation assays were performed with resting
cells of the wild type and the BW ΔaceK ΔcaiA p37cai
strain. Carnitine production was enhanced by resting
conditions in both strains. The productivities were 28.5
and 59.6 mmol l-1 · h-1 for the wild type and the BW
ΔaceK ΔcaiA p37cai mutant, respectively. The mutant
strain reached almost 100% conversion in less than two
hours (Figure 4), which is the highest conversion ever
reported for L(-)-carnitine producing E. coli strains.Effect of mutations on control points of the central
metabolism
The wild type and the BW ΔaceK ΔcaiA p37cai mutant
were selected to study the changes imposed by the gen-
etic modifications on central metabolism. To this end,
seven metabolites were analyzed: succinate, pyruvate, fu-
marate, lactate, acetate, ethanol, and formate. Major
changes were observed on acetate, which is the main
metabolic product and can be considered as readout of
the energetic state, and on succinate, which is a product
of the mixed acid fermentation pathway and also results
from fumarate respiration (Table 2).
In anaerobic cultures supplemented with fumarate, the
wild type and the mutant strain exhibited a similar be-
havior. The maximum concentration of succinate and
acetate coincided with the end of the exponential phase,
when the culture broth was completely depleted of
fumarate (12.2 and 13.9 mM succinate, and 10.2 and
16.4 mM acetate for the wild type and the overproducer
strain, respectively). Acetate decreased slightly during
the stationary phase. A similar behavior was observed in
the assays without fumarate. Formate was only detected
in the exponential phase, increasing steeply during the
first ten hours of culture, especially in the mutant strain.
It was not detected in the stationary phase of cultures,
which indicates the activity of formate hydrogen-lyase
(Fhl) under these conditions. Changes observed in the
fermentation profiles in anaerobic cultures are especially
relevant, since they reflect the energy state of cells. Thus,
the central metabolism of E. coli strains was focused on
maintaining suitable levels of ATP and free coenzyme A,
Table 2 Metabolic performance of wild-type (BW25113) and engineered (BW ΔaceK ΔcaiA p37cai) E. coli strains during
L(−)-carnitine production in anaerobic and aerobic conditions
Strain and conditions qL-car qSuc -qFum qAcet qEtOH qForm
Anaerobic cultures
LB-CB
BW25113 9.30 ± 0.12 8.43 ± 0.22 — 15.71 ± 0.28 7.23 ± 0.20 4.21 ± 0.14
BW ΔaceK ΔcaiA p37cai 18.87 ± 0.23*** 7.20 ± 0.17*** — 17.44 ± 0.16*** 2.49 ± 0.12*** 12.96 ± 0.42***
LB-CB + fumarate (12.5 mM)
BW25113 14.23 ± 0.15 13.89 ± 0.54 17.74 ± 0.26 13.15 ± 0.36 4.8 ± 0.32 N.D.
BW ΔaceK ΔcaiA p37cai 27.75 ± 0.17*** 10.31 ± 0.32*** 19.51 ± 0.41*** 16.44 ± 0.21*** 3.95 ± 0.27*** N.D.
Aerobic cultures
LB-CB
BW25113 — N.D. — 9.49 ± 0.23 0.43 ± 0.05 —
BW ΔaceK ΔcaiA p37cai 6.15 ± 0.10*** N.D. — 7.79 ± 0.12*** 1.17 ± 0.08* —
LB-CB + fumarate (12.5 mM)
BW25113 — 3.32 ± 0.11 9.42 ± 0.24 5.74 ± 0.10 0.15 ± 0.02 —
BW ΔaceK ΔcaiA p37cai 7.02 ± 0.07*** 2.95 ± 0.08 6.82 ± 0.17*** 8.31 ± 0.14*** 1.26 ± 0.06*** —
Specific production/consumption rates of L(−)-carnitine and the main extracellular metabolites were calculated during the early exponential phase of cultures. All
rates are expressed in mmol g-1 h-1. Pairwise statistical comparison of the parameters assessed for both strains was perfomed with ANOVA and Tukey tests.
Adjusted p-values are indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001.
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process.
The strains grown aerobically showed similar patterns
in the metabolite profiles, although differences were
found in the levels reached in the stationary phase. At
the beginning of the stationary phase, succinate and
acetate achieved their maximum concentration (8.3 and
18.1 mM, respectively, for the mutant; 7.4 and 12.5 mM,
respectively, for the wild type strain), emphasizing the
importance of the acetate metabolism. Moreover, acetate
decreased drastically in the later stationary phase, indi-
cating the activity of the acetate scavenging systemsFigure 4 L(−)-carnitine production by resting cells. The performance of
(black) strains is compared. Discontinuous line indicates the maximum prod
experiments were performed in phosphate buffered 50 mM crotonobetain[39-41]. Similar acetate profiles were observed in cul-
tures without fumarate. Under aerobic conditions,
acetate overflow highlights the need of maintaining the
acetyl-CoA/CoASH ratio to meet cellular demands.
Discussion
This work demonstrates the successful construction of
E. coli strains engineered for high yielding production of
L(-)-carnitine from crotonobetaine. Biotransformation
yields ranging from 40 to 95% were obtained in the
growing cells system, while conversion was almost
complete using resting cells. The strain optimizationthe BW25113 (wild type) (grey) and BW25113 ΔaceK ΔcaiA p37cai
uction (corresponding to 50 mM L(−)-carnitine). Resting cell
e, as explained in the Methods section.
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drawbacks previously identified. The modifications in-
troduced had a cumulative effect on strain performance,
improving yield and productivity without affecting
growth or physiology of the bacteria. In fact, the best re-
sults were obtained with the BW ΔaceK ΔcaiA p37cai
strain which had a growth profile similar to that of the
wild type strain.
Previous works demonstrated that the optimization of
the biotransformation process depends on primary and
secondary metabolisms and its regulation [15,18,34,42,43].
Knockout mutants on the glyoxylate shunt genes aceK
and aceA showed a modest increase in carnitine produc-
tion [34], underlining the importance of the TCA cycle
flux. However, its impact on the productivity was small
when compared to the overexpression of enzymes
performing the biotransformation such as CaiC and CaiB
[23,34,35] or the whole cai operon (this work).
The replacement of the promoter of the caiF gene
with the constitutive p8 promoter enhanced L(-)-carni-
tine production under aerobic and anaerobic conditions.
CaiF is a specific transcriptional activator of carnitine
metabolism, binding to two 11-bp inverted repeat half-
sites separated by 13 bp in the intergenic region of the
two operons caiTABCDE and fixABCX. The expression
of caiF is activated by cAMP-CRP and FNR which pre-
vents the expression of the trimethylammonium com-
pounds metabolism in the presence of oxygen and/or
glucose [28-30]. Transcriptional repression was over-
come after promoter replacement in BW p8caiF, al-
though this was not sufficient for optimal performance,
especially under aerobic conditions. Various reasons
can respond for this observed effect. For instance, al-
though the FNR binding site located at −55.5 bp in the
caiF promoter was replaced, the presence of further pu-
tative half sites for FNR binding is known, which role
on caiF expression is not known. In addition, the cai
promoter is also regulated by FNR (two sites at −90.5
and −41.5 bp, respectively) and ArcA (four sites located
at −101, -91, +28, and +50 bp) [44], and CaiF
overexpression could not be enough for optimal expres-
sion under aerobic conditions.
The most remarkable improvement was obtained by
tuning the expression of the cai operon and deleting
caiA gene. Replacement of the endogenous promoter by
the constitutive promoter p37 enhanced L(-)-carnitine
production under anaerobic and aerobic conditions, re-
lieving the cai operon from the regulatory effects of
oxygen and CaiF. Importantly, the formation of the side-
product γ-butyrobetaine was effectively avoided by
deleting caiA, redirecting crotonobetaine towards L
(-)-carnitine production [16,24]. This deletion led to a
25-60% enhancement in L(-)-carnitine production in the
BW ΔcaiA strain and a 30-87% enhancement in the BWΔaceK ΔcaiA p37cai strain. This is the best performing
strain obtained, achieving over 95% conversion of the
substrate in a growing system, and almost 100% of con-
version in a resting cells system.
When the effect of the metabolic engineering strategy
on the physiology of the bacteria was assessed, several
metabolic changes between the wild type and the BW
ΔaceK ΔcaiA p37cai strain were observed. Under anaer-
obic biotransformation conditions, energy producing
processes such as fumarate respiration [45,46] and acet-
ate and formate production [40,41,47-50] were enhanced
in the mutant. This supports the high dependence of L
(-)-carnitine production on the energetic state of cells
[15]. Although fumarate was originally used as electron
acceptor and inhibitor of the crotonobetainyl-CoA re-
ductase activity (CaiA) [15,24,33], media supplementa-
tion with this energetic substrate enhanced growth and
L(-)-carnitine production, even in ΔcaiA strains. There-
fore, the reduction of fumarate is a major mechanism of
ATP generation in anaerobic conditions [15,42,45], simi-
larly to aerobic oxidative phosphorylation. Increased
production of acetate (the end-product of the major en-
ergy producing anaerobic pathway of E. coli) and for-
mate (the end product of pyruvate-formate lyase) was
not observed in aerobic cultures, in which energy is pro-
duced by respiration and acetate production occurs as a
result of an overflow metabolism [39-41].
It is important to emphasize that the engineered
strains created in this work were able to carry out the
biotransformation under aerobic conditions, while no L
(-)-carnitine was produced by wild type E. coli. The best
performing strain was BW ΔaceK ΔcaiA p37cai with
65% of conversion, a 4-fold higher yield than that reported
in previous works under aerobic conditions [33,34]. Fast
growth and low biotransformation rate of the BW ΔaceK
ΔcaiA p37cai strain avoided complete conversion of
crotonobetaine. This suggests that other limitations in
central metabolism may occur. A plausible explanation for
the observed differences between both conditions could
be coenzyme A availability, as shown in previous works
[15,34,42].
Summarizing, we have successfully engineered E. coli
for efficient, high-yielding L(-)-carnitine production
from an inexpensive substrate (such as crotonobetaine).
A stable engineered strain was obtained, which does not
depend on expensive inducers (since the p37 and p8
promoters are constitutive) or antibiotics (since all
modifications are chromosomal, stable and antibiotic
marker-free). In addition, fast transformation was almost
complete, therefore with improved downstream process-
ing. Exploitation of this engineered strain in high-density
reactors is a feasible and economically viable strategy for
the implementation of L(-)-carnitine production pro-
cesses at the industrial scale.
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L(-)-carnitine production in E. coli based growing and
resting cells systems has been successfully improved.
Multiple stable mutations introduced in a single strain
enhanced production without reducing cell viability or
affecting specific growth. Furthermore, the biotechno-
logical process was improved and allowed nearly 100%
conversion reducing the time of transformation and
simplifying downstream processing. Moreover, the main
restriction to aerobic expression of the carnitine metabol-
ism was eliminated. This study presents a successful strain
improvement strategy by means of gene deletion and pro-
moter replacement and contributes to get further insights
into the secondary metabolism of trimethylammonium
compounds in E. coli.Methods
Strains and plasmids
The wild type strain E. coli BW25113 [lacIq rrnBT14
ΔlacZWJ16 hsdR514 ΔaraBADAH33 ΔrhaBADLD78] was
obtained from the Keio collection [51]. The mutant
strains constructed in the present study (Table 3) were
obtained as described below. The strains were stored in
50% glycerol at −80°C.
Standard E. coli cultures for molecular biology work
were performed in Luria-Bertani broth (LB). Antibiotics
(ampicillin 100 μg mL-1, kanamycin 30 μg mL-1, chloram-
phenicol 30 μg mL-1) were added whenever necessary.
The plasmids pKD46 (Red helper plasmid, Ampicillin
resistance), pKD3 (containing a FRT-flanked chloram-
phenicol resistance (cat) gene), pKD4 (containing a
FRT-flanked kanamycin resistance (kan) gene), pCP20
(expressing FLP recombinase activity) [52,53], and pKD-
Cre (expressing Cre recombinase activity) were obtained
from Prof. Dr. J-P Hernalsteens (Vrije Universiteit
Brussels, Belgium). The chloramphenicol resistant (cat)
gene flanked by loxP sites and the priming P1 and P2 sites
was cloned into pBlueScript using XbaI and BamHI
restrictions sites.Table 3 List of bacterial strains used in this work
Strain References
E. coli BW25113 Keio collection, Baba et al. [5
E. coli BW25113 ΔaceK This work
E. coli BW25113 ΔaceA This work
E. coli BW25113 ΔaceAK This work
E. coli BW25113 ΔcaiA This work
E. coli BW25113 ΔpcaiF caiF-p8 This work
E. coli BW25113 Δpcai cai-p37 This work
E. coli BW25113 ΔaceK Δpcai cai-p37 This work
E. coli BW25113 ΔaceK ΔcaiA Δpcai cai-p37 This workAll molecular biology experimentation and strain en-
gineering performed for the completion of this work
were approved by the Bioethics Committee of the Univer-
sity of Murcia and complies with all legal requirements.Strain engineering: gene knock-out and promoter knock-
in strategies
Standard molecular biology protocols were used [54].
Knockout mutants were constructed by successive
deletion of specifically targeted genes or regulatory re-
gions using the method of Datsenko and Wanner [53].
Targeted sequences were PCR-amplified using specific-
ally designed primers (see Additional file 1: Table S1)
and transformed into pKD46-carrying cells. Mutants
were selected for either kanamycin or chloramphenicol
resistance. The pCP20-encoding FLP recombinase pro-
tein or pKD-Cre-encoding Cre recombinase protein was
used to excise the antibiotic-resistance cassette. For the
mutation of both cai/fix and caiF promoters, the pro-
moter knock-in method was used [37]. The specific
strategy consisted in the replacement of the respective
endogenous promoter sequences by synthetic promoters.
Knock-in mutants were constructed from these deletion
strains. Two constitutive promoters with different strength
were tested for the tuning strategy: p37 (strong) and p8
(weak). These synthetic promoters have been previously
described [38] (Figure 2). The mutant strains constructed
are listed in Table 3. All constructions were checked by
PCR and DNA sequencing.Culture conditions
For the biotransformation of L(-)-carnitine from cro-
tonobetaine, a pre-culture was grown at 37°C aerobically
using LB medium, pH adjusted to 7.5 with KOH prior to
autoclaving (LB). The cultures were inoculated with 3%
(v/v) of an overnight grown pre-culture. Cultures were
grown under both aerobic and anaerobic conditions at
37°C in LB medium supplemented with 50 mM cro-
tonobetaine as substrate (LB-CB). In some cultures,Genotype Short name
1] lacIq rrnBT14 ΔlacZWJ16 hsdR514
ΔaraBADAH33 ΔrhaBADLD78
BW25113
[BW25113] ΔaceK BW ΔaceK
[BW25113] ΔaceA BW ΔaceA
[BW25113] ΔaceAK BW ΔaceAK
[BW25113] ΔcaiA BW ΔcaiA
[BW25113] ΔpcaiF::caiF-p8 BW p8caiF
[BW25113] Δpcai::cai-p37 BW p37cai
[BW25113] ΔaceK Δpcai::cai-p37 BW ΔaceK p37cai
[BW25113] ΔaceK ΔcaiA Δpcai::cai-p37 BW ΔaceK ΔcaiA p37cai
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and as inhibitor of the reaction catalyzed by the
crotonobetainyl-CoA reductase (CaiA). Batch anaerobic
assays were performed in 100 mL vessels with 60 mL
working volume under nitrogen atmosphere and mag-
netic stirring. Aerobic assays were performed in 250 mL
erlenmeyer flasks with 50 mL working volume in a ro-
tary shaker (150 rpm). The experiments were performed
in triplicate.
Resting cells
For the resting cell assays, anaerobic cultures in LB
medium with 5 mM of crotonobetaine, used as inducer of
cai operon, were harvested at the end of the exponential
growth phase, centrifuged at 16,000xg for 10 min, and
washed twice with 67 mM potassium phosphate buffer,
pH 7.5. Cells were resuspended in 50 mM potassium
phosphate buffer, pH 7.5 with 50 mM crotonobetaine and
incubated at 37°C in erlenmeyer flasks in a rotary shaker
(150 rpm). All experiments were performed at least in
triplicate and under sterile conditions.
Analytical procedures
Cell growth was followed by optical density (OD) at
600 nm with a spectrophotometer (Novaspec II;
Pharmacia-LKB, Sweden) and converted to dry cell
weight (DWC). For L(-)-carnitine and extracellular me-
tabolite analysis, cell-free supernatant was obtained by
centrifugation at 19,000xg for 10 min. L(-)-carnitine con-
centration was determined with an enzymatic assay [32].
γ-Butyrobetaine was determined by HPLC [32] with a
Spherisorb-NH2 column (3 μm, 4.6 × 150 mm) supplied
by Waters (Barcelona, Spain). The isocratic mobile phase
was acetonitrile/H3PO4 0.005 M pH 5.5 (65/35) at a flow
rate of 1 mL min-1. For the analysis of fermentation
products (acetate, ethanol, formate, fumarate, pyruvate,
and succinate), a cation exchange Aminex HPX-87H col-
umn supplied by BioRad Labs (Hercules, CA) was used.
The isocratic mobile phase was 5 mM H2SO4 at a flow
rate of 0.5 mL min-1. A HPLC system from Shimadzu
(Kyoto, Japan) was used. The effluent was monitored
using diode array and refractive index detectors
(Shimadzu, Kyoto, Japan).
RNA isolation and quantitative PCR
RNA was isolated at mid-exponential phase, when L
(-)-carnitine production rate was maximum. The cul-
tures were pelleted by centrifugation at 15,000 × g at 4°C
for 30 s. Total RNA was isolated by Qiagen Rneasy®Mini
Kit (QIAGEN Ibérica, Madrid, Spain). Additionally,
DNaseI digestion of the isolated RNA was performed
using the RNase-free DNase Set (QIAGEN Ibérica,
Madrid, Spain) to avoid DNA interferences during PCR
steps. RNA quality and quantity were evaluated bymicrofluidic capillary electrophoresis on an Agilent 2100
Bioanalyzer (Agilent Technologies, PaloAlto, CA) using
Agilent RNA 6000 Pico kit. The primers used in this
work were designed using the PrimerExpress® Software
v3.0 (Applied Biosystems, FosterCity, CA) and ordered
from Sigma–Aldrich Co (St. Louis, USA) (see Additional
file 1: Table S1). The dnaA (encoding the multifunc-
tional initiator of chromosome replication and transcrip-
tional regulator) and polA genes (encoding the DNA
polymerase I) were used as HKG. Quantitative PCR was
performed in a 7300 Real-Time PCR System (Applied
Biosystems,Foster City, CA) using PowerSYBR®Green
PCR Master Mix (Applied Biosystems, Foster City, CA).
Samples were run in triplicate. Raw data were transformed
into threshold cycle (Ct) values. Relative gene expression
was calculated by the comparative Ct method (ΔΔCt). Ex-
periments were performed in triplicate.
Statistical analysis of data
The statistical analyses were carried out using R (version
2.15.1). A one-way ANOVA was applied to determine
the differences among different conditions and strains. A
Tukey test was also carried out to ascertain the signifi-
cant differences between data pairs. The threshold p-
value chosen for statistical significance was p < 0.05.
Additional file
Additional file 1: Table S1. Primers used for real time PCR. The primers
used in this work were designed using the Primer Express® Software v3.0
(Applied Biosystems, Foster City, CA) and ordered from Sigma-Aldrich
(Sigma-Aldrich Co., St. Louis, USA). The dnaA and polA genes (encoding
the multifunctional initiator of chromosomal replication and
transcriptional regulator and DNA polymerase I, respectively) were used
as internal control for relative quantification.
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